BioScrip Inc. (NASDAQ:BIOS) fell 5% on Tuesday . The stock traded as low as $2.45 and last traded at $2.45, with a volume of 422,135 shares changing hands. The stock had previously closed at $2.58.

Separately, Zacks Investment Research raised shares of BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Monday, July 11th.

The stock’s 50-day moving average price is $2.57 and its 200 day moving average price is $2.33. The firm’s market capitalization is $172.64 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.05. During the same period in the prior year, the company posted ($0.17) EPS. The business had revenue of $238.50 million for the quarter, compared to analyst estimates of $232.38 million. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, equities analysts anticipate that BioScrip Inc. will post ($0.20) EPS for the current fiscal year.

In other BioScrip news, Director David W. Golding acquired 12,500 shares of the company’s stock in a transaction that occurred on Friday, June 17th. The shares were bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the completion of the acquisition, the director now owns 42,500 shares in the company, valued at approximately $105,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Coliseum Capital Management, L acquired 4,200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 22nd. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Diamond Hill Capital Management Inc. raised its position in BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned 4.44% of BioScrip worth $5,347,000 as of its most recent SEC filing.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.